<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="52083">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT02063230</url>
  </required_header>
  <id_info>
    <org_study_id>D1532C00082</org_study_id>
    <nct_id>NCT02063230</nct_id>
  </id_info>
  <brief_title>To Assess the Pharmacokinetics, Safety and Tolerability of Selumetinib in Patients With Hepatic Impairment and Healthy Subjects</brief_title>
  <official_title>An Open-label, Comparative Study to Assess the Pharmacokinetics, Safety and Tolerability of Selumetinib (AZD6244, ARRY-142886) (Hyd-Sulfate) Following Single Oral Dosing to Healthy Subjects and to Subjects With Mild, Moderate, and Severe Hepatic Impairment</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>AstraZeneca</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>AstraZeneca</source>
  <oversight_info>
    <authority>United States: Food and Drug Administration</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      A study to assess the pharmacokinetics, safety and tolerability of Selumetinib (AZD6244,
      ARRY-142886) in patients with hepatic impairment and healthy subjects.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      An open label study to assess the pharmcokinetics, safety and tolerability of a single dose
      of Selumetinib (AZD6244, ARRY-142886) in patients with hepatic impairment and healthy
      subjects.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>March 2014</start_date>
  <completion_date type="Anticipated">September 2014</completion_date>
  <primary_completion_date type="Anticipated">September 2014</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Basic Science</study_design>
  <primary_outcome>
    <measure>Description of the pharmakocinetic (PK) profile in terms of maximum observed plasma concentration (Cmax), area under plasma concentration-time curve from zero extrapolated to infinity (AUC)</measure>
    <time_frame>Samples will be taken at Visit 2 predose, 30min, 1h, 1h 30 min, 2h, 2h 30min, 3h,3h 30 min, 4h,6h,8h,12h,24h,36h,48h,72h,76h,120h</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <primary_outcome>
    <measure>Description of the pharmakocinetic (PK) profile in terms of area under plasma concentration-time curve to time of last measurable concentration (AUC(0 t))</measure>
    <time_frame>Samples will be taken at Visit 2 predose, 30min, 1h, 1h 30 min, 2h, 2h 30min, 3h,3h 30 min, 4h,6h,8h,12h,24h,36h,48h,72h,76h,120h</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>Description of the safety profile in terms of adverse events, physical examinations, ophthalmology assessments, vital signs, clinical laboratory assessments and 12 lead electrocardiograms.</measure>
    <time_frame>From screening to followup (approximately 6weeks)</time_frame>
    <safety_issue>Yes</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Description of the PK profile in terms of dose-normalized maximum observed plasma concentration (Cmax_D)</measure>
    <time_frame>Samples will be taken at Visit 2 predose, 30min, 1h, 1h 30 min, 2h, 2h 30min, 3h,3h 30 min, 4h,6h,8h,12h,24h,36h,48h,72h,76h,120h</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Description of the PK profile in terms of dose-normalized area under plasma concentration-time curve from zero extrapolated to infinity (AUC_D)</measure>
    <time_frame>Samples will be taken at Visit 2 predose, 30min, 1h, 1h 30 min, 2h, 2h 30min, 3h,3h 30 min, 4h,6h,8h,12h,24h,36h,48h,72h,76h,120h</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Description of the PK profile in terms of dose-normalized area under plasma concentration-time curve to time of last measurable concentration (AUC(0 t)_D)</measure>
    <time_frame>Samples will be taken at Visit 2 predose, 30min, 1h, 1h 30 min, 2h, 2h 30min, 3h,3h 30 min, 4h,6h,8h,12h,24h,36h,48h,72h,76h,120h</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Description of the PK profile in terms of mean residence time (MRT) and time to maximal observed concentrations (tmax)</measure>
    <time_frame>Samples will be taken at Visit 2 predose, 30min, 1h, 1h 30 min, 2h, 2h 30min, 3h,3h 30 min, 4h,6h,8h,12h,24h,36h,48h,72h,76h,120h</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Description of the PK profile in terms of area under plasma concentration-time curve from zero to twelve hours (AUC(0-12))</measure>
    <time_frame>Samples will be taken at Visit 2 predose, 30min, 1h, 1h 30 min, 2h, 2h 30min, 3h,3h 30 min, 4h,6h,8h,12h</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Description of the PK profile in terms of terminal half-life (t½), terminal elimination rate constant (λz), apparent oral clearance (CL/F) and apparent steady-state volume of distribution (Vss/F)</measure>
    <time_frame>Samples will be taken at Visit 2 predose, 30min, 1h, 1h 30 min, 2h, 2h 30min, 3h,3h 30 min, 4h,6h,8h,12h,24h,36h,48h,72h,76h,120h</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Description of the PK profile in terms of apparent volume of distribution (Vz/F), fraction unbound (fu), average fraction unbound (fu,av)</measure>
    <time_frame>Samples will be taken at Visit 2 predose, 30min, 1h, 1h 30 min, 2h, 2h 30min, 3h,3h 30 min, 4h,6h,8h,12h,24h,36h,48h,72h,76h,120h</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Description of the PK profile in terms of free Cmax (Cmax,u), dose-normalized free Cmax (Cmax,u_D), free AUC (AUCu), dose-normalized free AUC (AUCu_D) and free AUC(0 t) (AUC(0 t)u)</measure>
    <time_frame>Samples will be taken from each urine collection period at visit 2 : from -12 to 0 (predose), and 0 to 6, 6 to 12, 12 to 24, 24 to 36, 36 to 48 hours, and every 24 hours thereafter up to 120 hours.</time_frame>
    <safety_issue>No</safety_issue>
    <description>If it is not believed that any meaningful recovery or quantifiable levels for any analyte was achieved, analysis will only continue up to 48 hours.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Description of the PK profile in terms of dose-normalized free AUC(0 t)u (AUC(0 t)u_D), unbound CL/F (CL/Fu) and amount of drug excreted into the urine (Ae)</measure>
    <time_frame>Samples will be taken from each urine collection period at visit 2: from -12 to 0 (predose), and 0 to 6, 6 to 12, 12 to 24, 24 to 36, 36 to 48 hours, and every 24 hours thereafter up to 120 hours.</time_frame>
    <safety_issue>No</safety_issue>
    <description>If it is not believed that any meaningful recovery or quantifiable levels for any analyte was achieved, analysis will only continue up to 48 hours.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Description of the PK profile in terms of cumulative amount recovered in urine from time zero to the last quantifiable time point (Ae(0-t)), percent of dose excreted in urine (fe), and renal clearance (CLR)</measure>
    <time_frame>Samples will be taken from each urine collection period at visit 2: from -12 to 0 (predose), and 0 to 6, 6 to 12, 12 to 24, 24 to 36, 36 to 48 hours, and every 24 hours thereafter up to 120 hours.</time_frame>
    <safety_issue>No</safety_issue>
    <description>If it is not believed that any meaningful recovery or quantifiable levels for any analyte was achieved, analysis will only continue up to 48 hours.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Description of the metabolite profiles if appropriate in terms of Cmax, Cmax_D , tmax, AUC(0-12), AUC(0-t), AUC(0-t)_D, AUC, AUC_D, t½, λz, Ae, Ae(0-t), fe, and CLR and the metabolite to parent AUC and Cmax ratios (MRAUC and MRCmax).</measure>
    <time_frame>Samples will be taken at Visit 2 predose, 30min, 1h, 1h 30 min, 2h, 2h 30min, 3h,3h 30 min, 4h,6h,8h,12h,24h,36h,48h,72h,76h,120h</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">32</enrollment>
  <condition>Solid Tumors</condition>
  <arm_group>
    <arm_group_label>Selumetinib HV</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Healthy volunteers (HV)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Selumetinib mild impairment</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Mild (Child Pugh A) hepatic impaired patients</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Selumetinib moderate impairment</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Moderate (Child Pugh B) hepatic impaired patients</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Selumetinib severe impairment</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Severe (Child Pugh C) hepatic impairment patients</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Selumetinib 50mg</intervention_name>
    <description>HV and hepatic impaired patients with mild and moderat severity will recived selumetinib 50mg orally on day 1</description>
    <arm_group_label>Selumetinib HV</arm_group_label>
    <arm_group_label>Selumetinib mild impairment</arm_group_label>
    <arm_group_label>Selumetinib moderate impairment</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Selumetinib 25mg</intervention_name>
    <description>Severe (Child Pugh C) hepatic impaired patients will receive selumetinib 25mg orally on Day 1</description>
    <arm_group_label>Selumetinib severe impairment</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria for all participants:

          1. Subjects will be males or females (non-childbearing potential) aged 18 years or more
             and with a weight of at least 45 kg and a BMI between 18 and 40 kg/m2 inclusive.

             Inclusion Critera only for hepatic impaired patients:

          2. Subjects with stable liver cirrhosis and hepatic impairment for at least 3 months
             prior to the start of the study.

             Inclusion Criteria only for healthy volunteers:

          3. Subjects must be in good health, as determined by a medical history, physical
             examination, 12-lead ECG, clinical laboratory evaluations, and an ophthalmic
             examination performed before the administration of the investigational product.

        Exclusion Criteria for all participants:

          1. Subjects of Japanese or non-Japanese Asian ethnicity

          2. Any one parent or grandparent (maternal or paternal) is Japanese or non-Japanese
             Asian (eg, China, Taiwan, Korea, Philippines, Thailand, Vietnam, and Malaysia).
             Asian Indians are acceptable.

          3. Any clinically important illness, medical/surgical procedure, or trauma within 4
             weeks of the first administration of the investigational product

          4. Subjects who smoke more than 10 cigarettes or the equivalent in tobacco per day.

             Exclusion criteria for hepatic impaired patients only

          5. Undergone liver transplantation. -
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Thomas C Marbury, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Orlando Clinical Research Center, 5055 S Orange Avenue, Orlando, Florida, United States.</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Ian Smith, MD</last_name>
    <role>Study Director</role>
    <affiliation>Astrazeneca, UK</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Quintiles Drug Research Unit Call Center</last_name>
    <phone>0800 634 1132</phone>
    <email>ClinicalTrialTransparency@astrazeneca.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Orlando</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2014</verification_date>
  <lastchanged_date>May 26, 2014</lastchanged_date>
  <firstreceived_date>February 13, 2014</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Phase I, healthy, pharmacokinetic, hepatic impairment</keyword>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>No</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Liver Diseases</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
